Implications thérapeutiques des inhibiteurs du VEGF dans le cancer colorectal

Translated title of the contribution: Therapeutic strategies using VEGF inhibitors in colorectal cancer

Valérie Boige, David Malka, Michel Ducreux

Research output: Contribution to journalReview articlepeer-review

7 Scopus citations


Angiogenesis, a complex, coordinated process resulting in the assembly and maturation of new bloodvessels, is critical for the growth of tumors. Several lines of evidence argue for angiogenesis inhibition in the treatment of colorectal cancer (CRC): 1) angiogenesis (as measured by microvessel count), and the expression of pro-angiogenesis factors, such as vascular endothelial growth factor (VEGF), the key regulator of normal and pathological angiogenesis, have been reported to correlate with advanced disease and a worse prognosis; 2) the expression of VEGF has been shown to correlate with RAS mutations, alterations in the APC-WNT signaling pathway, and overexpression of cyclo-oxygenase-2, which all are frequent in CRC: 3) bevacizumab, a humanized anti-VEGF monoclonal antibody, is a potent inhibitor of tumor growth of various CRC cell lines in murine xenografts; 4) the addition of bevacizumab to systemic chemotherapy has been shown to be significantly superior to chemotherapy alone in terms of objective tumor response rate, progression-free survival, and overall survival in patients with metastatic CRC, in the frontline, and more recently in the second-line setting, without worsening of chemotherapy-related toxicity. However, several potential specific adverse events, such as thrombosis, hemorrhages, proteinuria, arterial hypertension, and bowel perforations have been described. Whether the antitumoral efficacy of bevacizumab could be increased when combined to low-dose (metronomic) chemotherapy, or radiotherapy (in rectal cancer), is under development, as well other VEGF-targeted approaches (e.g., dominantnegative mutants, antisense oligonucleotides, antibodies directed against VEGF receptors (VEGFR), VEGFR tyrosine kinase inhibitors, soluble VEGFR,...), or other anti-angiogenesis agents (e.g., thalidomide, celecoxib, angiozyme...).

Translated title of the contributionTherapeutic strategies using VEGF inhibitors in colorectal cancer
Original languageFrench
Pages (from-to)S29-S36
JournalBulletin du Cancer
Issue numberSPEC. ISS.
StatePublished - Sep 2005
Externally publishedYes


  • Angiogenesis
  • Antiangiogenic agent
  • Colorectal cancer
  • VEGF
  • VEGF inhibitor


Dive into the research topics of 'Therapeutic strategies using VEGF inhibitors in colorectal cancer'. Together they form a unique fingerprint.

Cite this